


PSYCHEDELIC RESEARCH SNAPSHOT

ON MINIMIZING RISK AND HARM IN THE USE OF PSYCHEDELICS

A study on safety, harm reduction, and research needs for psychedelic-assisted therapy.








Psychedelic use is rising




Risks remain poorly understood



Better safety measures are needed







What are Psychedelics?

Each has unique effects and risk profiles.

Classic Psychedelics

Psilocybin LSD Mescaline DMT

Non-classic Psychedelics

MDMA Ketamine Ibogaine





TYPES OF POTEINTIAL PSYCHOLOGICAL HARMS




Emotional Issues





Psychotic Episodes



Existential Confusion









TYPES OF POTENTIAL PSYCHOLOGICAL HARMS



SOCIAL DISCONNECTION





HALLUCINOGEN
PERSISTING PERCEPTION
DISORDER







INTERPERSONAL HARM



Psychedelic harms: How common are they?








Certain symptoms may persist for weeks, months, or years

What Increases Risk?





Individual biology, genetics, neurochemistry



Psychological trauma, mental health conditions



Medicinal
vs
recreational
use



POST-PSYCHEDELIC SUPPORT

Key Strategies




Online Information Resources




Affordable Therapy



Psychiatric Consultation







KEY TAKEAWAYS



Psychedelics offer promise but carry risks



More research and safety measures are needed



Industry and policymakers must support harm reduction

A safer psychedelic future requires collaboration, research, and responsibility.





On Minimizing Risk and Harm in the Use of Psychedelics.

Psychiatric Research and Clinical Practice, 2025, 1–5.

Evans, J., Aixalà, M., Anderson, B. T., Brennan, W., Bremler, R., Breeksema, J. J., Burback, L., Calder, A. E., Carhart-Harris, R. L., Cheung, K., Devenot, N., Gorman, I., Greń, J., Hendricks, P. S., Holoyda, B., Jacobs, E., Krecké, J., Kruger, D. J., Luke, D., ... Yaden, D. B. (2025).

DOI: 10.1176/appi.prcp.20240128

